FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to drugs and concerns a pharmaceutical composition used for treatment or control of bacterial infections. Compositions used by parenteral administration route comprises the effective amounts of (a) piperacillin or its pharmaceutically acceptable salt; (b) tazobactam or its pharmaceutically acceptable salt, and (c) at least one chelate-forming agent chosen from group consisting of ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), nitrilotriacetic acid (NTA), O,O'-bis-(2-aminoethyl)-ethylene glycol-N,N,N',N'-tetraacetic acid (EGTA), trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CyDTA), and their pharmaceutically acceptable salts. Also, invention proposes a method for preparing a pharmaceutical composition to be subjected for dilution. Use of a chelate-forming agent in the combination piperacillin/tazobactam provides inhibition of formation of particles in its mixing with aminoglycoside antibiotics.
EFFECT: improved and valuable pharmaceutical properties of composition.
62 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
INTENDED FOR INJECTION COMPOSITIONS FOR OVERCOMING BETA-LACTAMASE-MEDIATED RESISTANCE TO ANTIBIOTICS WITH APPLICATION OF BETA-LACTAMASE INHIBITOR | 2005 |
|
RU2397768C2 |
CEFTAROLINE-INCLUDING COMPOSITIONS AND METHODS OF TREATMENT | 2009 |
|
RU2524665C2 |
PHARMACEUTICAL PREPARATIVE FORM | 2004 |
|
RU2362560C2 |
SOLID FORMS OF CEFTOLOZANE | 2014 |
|
RU2703457C2 |
COMPOSITIONS CONTAINING ANTIBACTERIAL AGENT AND TAZOBACTAM | 2011 |
|
RU2593363C2 |
TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS | 2013 |
|
RU2671485C2 |
ANTIBACTERIAL COMPOSITIONS | 2017 |
|
RU2813568C2 |
METHOD FOR CLEANING FIBRINOGEN, FIBRINOGEN PRODUCT AND MEANS FOR CLEANING OR PRODUCING FIBRINOGEN PRODUCT | 2013 |
|
RU2663792C2 |
ANTIBIOTIC FORMULATION CONTAINING BETA-LACTAMES AND BUFFER INGREDIENTS | 2007 |
|
RU2459625C2 |
COMBINED THERAPEUTIC AGENTS CONTAINING OXAZOLIDINONES-QUINOLONES INTENDED FOR TREATMENT OF BACTERIAL INFECTIONS | 2014 |
|
RU2675847C2 |
Authors
Dates
2008-04-27—Published
2004-04-06—Filed